|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2100049814 |
|
最近更新日期: Date of Last Refreshed on: |
2021-08-10 01:11:18 |
|
注册时间: Date of Registration: |
2021-08-10 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
银离子抗菌功能性敷料治疗皮肤深度Ⅱ烧烫伤创面的有效性及安全性临床试验 |
|
Public title: |
Clinical trial of efficacy and safety of Silver Ion Antibacterial Functional Dressing in the treatment of deep second degree burn wounds |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
银离子抗菌功能性敷料治疗皮肤深度Ⅱ烧烫伤创面的有效性及安全性临床试验 |
|
Scientific title: |
Clinical trial of efficacy and safety of Silver Ion Antibacterial Functional Dressing in the treatment of deep second degree burn wounds |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
何杰 |
研究负责人: |
谢卫国 |
|
Applicant: |
He Jie |
Study leader: |
Xie Weiguo |
|
申请注册联系人电话: Applicant telephone: |
+86 0731-89672566 |
研究负责人电话:
Study leader's |
+86 18071085225 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
625363979@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
wgxie@hotmail.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
湖南省长沙市高新开发区谷苑路229号海凭国际医疗器械产业园A4栋5-8层 |
研究负责人通讯地址: |
湖北武汉市武昌区彭刘杨路241号 |
|
Applicant address: |
5-8 Floor, A4 International Medical Instrument Industrial Park, Hunan Lugu Road, No. 229, Valley Road, Changsha Hi-tech Development Zone, Changsha, Hu'nan,bChina |
Study leader's address: |
241 Pengliuyang Road, Wuchang District, Hubei, China |
|
申请注册联系人邮政编码: Applicant postcode: |
410000 |
研究负责人邮政编码: Study leader's postcode: |
430061 |
|
申请人所在单位: |
长沙海润生物技术有限公司 |
||
|
Applicant's institution: |
Changsha Hairun Biotechnology Co.,Ltd. |
||
|
研究负责人所在单位: |
武汉市第三医院 |
||
|
Affiliation of the Leader: |
Wuhan Thrid Hospital-Tongren Hospital of Wuhan University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2018伦审字(25)-年1 |
伦理委员会批件附件: Approved file of Ethical Committee: |
|
|
批准本研究的伦理委员会名称: |
武汉市第三医院伦理委员会 |
||
|
Name of the ethic committee: |
The ethics committee of Wuhan Thrid Hospital-Tongren Hospital of Wuhan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2020-05-13 00:00:00 | ||
|
伦理委员会联系人: |
安靖 |
||
|
Contact Name of the ethic committee: |
An Jing |
||
|
伦理委员会联系地址: |
武汉市武昌区彭刘杨路241号 |
||
|
Contact Address of the ethic committee: |
241 Pengliyang Road, Wuchang District, Wuhan, Hubei, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 027-68894978 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
syylunli@163.com |
|
研究实施负责(组长)单位: |
武汉市第三医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Wuhan Thrid Hospital-Tongren Hospital of Wuhan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
武汉市武昌区彭刘杨路241号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
241 Pengliyang Road, Wuchang District, Wuhan, Hubei, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-raised funds |
||||||||||||||||||||||
|
研究疾病: |
皮肤深度Ⅱ烧烫伤创面 |
||||||||||||||||||||||
|
Target disease: |
Deep second degree burn wounds |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
I期临床试验 | ||||||||||||||||||||||
|
Study phase: |
1 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
验证长沙海润生物技术有限公司生产的银离子抗菌功能性敷料治疗皮肤深Ⅱ度烧烫伤创面的有效性及安全性。 |
||||||||||||||||||||||
|
Objectives of Study: |
To verify the efficacy and safety of silver ion antibacterial functional dressing produced by Changsha Hairun Biotechnology Co.,Ltd. in the treatment of deep second degree burn wounds. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
长沙海润生物技术有限公司生产的“银离子抗菌功能性敷料”与德国Paul Hartmann AG(保赫曼)公司生产的同类产品“含银敷料”分别应用在皮肤的深Ⅱ度烧烫伤创面,观测创面局部变化、愈合时间、愈合率的情况,并进行细菌学检查,计算总显效率,评价“银离子抗菌功能性敷料”对促进深Ⅱ度烧烫伤口的愈合作用是否非劣于已上市同类产品“含银敷料”,从而评判“银离子抗菌功能性敷料”的临床效果。 同时,通过检测实验室指标(如血常规、尿常规、肝肾功能、血糖(葡萄糖)等),并观测有无全身反应、局部皮肤/组织有无刺激性、创面肿胀、创面疼痛、局部皮肤颜色有无改变以及随时观测不良事件来评价其安全性;另外通过检测敷料使用前后不同时间点的血银和尿银情况,来评价银离子在体内的蓄积风险。 |
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
"Silver Ion Antibacterial Functional Dressing" (produced by Changsha Hairun Biotechnology Co.,Ltd.), and the similar products "Atrauman? Ag (produced by Paul Hartmann AG (Hartmann)) were applied on the deep second degree burn wounds, observing wound local changes, healing time and healing rate, and the bacteriology inspection, calculate the total efficiency, To evaluate whether the effect of "Silver Ion Antibacterial Functional Dressing" on promoting the healing of deep second degree burns is not worse than that of the similar product "Atrauman? Ag" which has been marketed, so as to evaluate the clinical effect of "Silver Ion Antibacterial Functional Dressing". At the same time, the safety was evaluated by testing laboratory indicators (such as blood routine examination, urine routine examination, liver and kidney function, blood glucose (glucose), etc.), and observing whether there were systemic reactions, local skin/tissue irritation, wound swelling, wound pain, local skin color change, and observing adverse events at any time. In addition, blood silver and urine silver were detected at different time points before and after dressing to evaluate the risk of silver ion accumulation in the body. |
||||||||||||||||||||||
|
纳入标准: |
(1)年龄18~65岁(包括边界值),性别不限; |
||||||||||||||||||||||
|
Inclusion criteria |
(1) Age 18-65 years (including the boundary value), gender is not limited; |
||||||||||||||||||||||
|
排除标准: |
(1)烧烫伤原因为电化学烧伤、射线烧伤; |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) The causes of burn were electrical discharge burn, chemical burns, and radiation burn; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2019-09-09 00:00:00至 To 2021-10-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2019-12-01 00:00:00 至 To 2021-05-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
受试者签署知情同意书后即可参加筛选体检,并按照签署知情同意书的先后顺序给予“筛选号”。各研究中心筛选的受试者筛选号从HT1801-XX-S001开始,“XX”为临床试验机构代号(如研究负责单位武汉市第三医院临床试验机构代号为“01”,详见“2多中心临床试验所有临床试验机构和研究者列表”)。筛选成功的受试者按照筛选号的先后顺序给予各中心分配到的“试验号”(如“HT1801-001”)。 以试验号为标识信息,采用区组随机的方法,将各中心入组的受试者随机分配至试验组和对照组,每组人数相等。随机方法中的区组长度、区组数等具体信息在受试者随机分组表中另行规定。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
After signing the "informed consent", the subjects can participate in screening physical examination, and the "screening number" will be given in the order of signing the "informed consent:". The selection number of subjects to be selected in each study center starts from HT1801-XX-S001, and "XX" is the code |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
除创面面积评估的研究医生和生物样本分析测试人员外,其他人员如临床研究者、项目管理人员、项目监查人员、数据管理及统计分析人员等均不设盲。对创面面积的评估由组长单位指定两名不参与试验操作的研究医生分别进行阅片,盲态评估,取两人计算的创面面积平均值。生物样本分析测试人员将采用盲态分析,在样本分析测试过程中不知道受试者随机编码及给药制剂。 |
|
Blinding: |
In addition to the research doctors for wound area assessment and biological sample analysis and testing personnel, other personnel such as clinical researchers, project managers, project supervisors, data management and statistical analysis personnel are not blind. For the assessment of wound area, the team leader designated two study doctors who did not participate in the experimental operation to read the film and conduct blind assessment respectively, and the average wound area calculated by the two doctors was taken. The biological sample analysis tester will perform blind analysis, in which the subject is randomly coded and the drug is administered without knowing during the sample analysis test. |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2023年12月 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
In December 2023 |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例原始记录保存在医院 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Cases of the original records in the hospital |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |